Myriad Genetics, Inc. announced that a study published in the Journal of Clinical Psychopharmacology found that the GeneSight® Psychotropic Test significantly reduced psychiatric hospitalizations in ...

SALT LAKE CITY, July 12, 2022 (GLOBE NEWSWIRE) -- Major Depressive Disorder (MDD) remission rates were significantly improved when clinicians had access to GeneSight ® Psychotropic test results from ...

SALT LAKE CITY, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, announced enhancements to the GeneSight ® Psychotropic test, ...

Myriad Genetics (NASDAQ:MYGN) executives highlighted fourth quarter and full-year 2025 results alongside a slate of planned ...

SALT LAKE CITY, April 21, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc (MYGN). (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that the Journal of ...

Myriad Genetics (MYGN) announced that the Journal of Clinical Psychopharmacology has published a study showing those with major depressive disorder had fewer psychiatric hospitalizations after taking ...

MASON, Ohio — Finding the right medication to treat mental health is often a frustrating game of trial and error between a patient and their healthcare provider. A ...

Highl ights Fourth quarter 2025 revenue of $209.8 million was consistent with fourth quarter 2024 revenue, but grew 4% year-over-year when ...